HotCopper Corporate Spotlight: Interview with Bob Proulx, CEO Imagion Biosystems (ASX:IBX) discussing their medical imaging technology being designated by the FDA as a breakthrough device.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal